Fcγ receptor-dependent antibody effector functions are required for vaccine protection against infection by antigenic variants of SARS-CoV-2

Emerging SARS-CoV-2 variants with antigenic changes in the spike protein are neutralized less efficiently by serum antibodies elicited by legacy vaccines against the ancestral Wuhan-1 virus. Nonetheless, these vaccines, including mRNA-1273 and BNT162b2, retained their ability to protect against seve...

Full description

Saved in:
Bibliographic Details
Published inbioRxiv
Main Authors Mackin, Samantha R, Desai, Pritesh, Whitener, Bradley M, Karl, Courtney E, Liu, Meizi, Baric, Ralph S, Edwards, Darin K, Chicz, Taras M, McNamara, Ryan P, Alter, Galit, Diamond, Michael S
Format Journal Article Paper
LanguageEnglish
Published United States Cold Spring Harbor Laboratory Press 28.11.2022
Cold Spring Harbor Laboratory
Edition1.1
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Emerging SARS-CoV-2 variants with antigenic changes in the spike protein are neutralized less efficiently by serum antibodies elicited by legacy vaccines against the ancestral Wuhan-1 virus. Nonetheless, these vaccines, including mRNA-1273 and BNT162b2, retained their ability to protect against severe disease and death, suggesting that other aspects of immunity control infection in the lung. Although vaccine-elicited antibodies can bind Fc gamma receptors (FcγRs) and mediate effector functions against SARS-CoV-2 variants, and this property correlates with improved clinical COVID-19 outcome, a causal relationship between Fc effector functions and vaccine-mediated protection against infection has not been established. Here, using passive and active immunization approaches in wild-type and Fc-gamma receptor (FcγR) KO mice, we determined the requirement for Fc effector functions to protect against SARS-CoV-2 infection. The antiviral activity of passively transferred immune serum was lost against multiple SARS-CoV-2 strains in mice lacking expression of activating FcγRs, especially murine FcγR III (CD16), or depleted of alveolar macrophages. After immunization with the preclinical mRNA-1273 vaccine, protection against Omicron BA.5 infection in the respiratory tract also was lost in mice lacking FcγR III. Our passive and active immunization studies in mice suggest that Fc-FcγR engagement and alveolar macrophages are required for vaccine-induced antibody-mediated protection against infection by antigenically changed SARS-CoV-2 variants, including Omicron strains.
AbstractList Emerging SARS-CoV-2 variants with antigenic changes in the spike protein are neutralized less efficiently by serum antibodies elicited by legacy vaccines against the ancestral Wuhan-1 virus. Nonetheless, these vaccines, including mRNA-1273 and BNT162b2, retained their ability to protect against severe disease and death, suggesting that other aspects of immunity control infection in the lung. Although vaccine-elicited antibodies can bind Fc gamma receptors and mediate effector functions against SARS-CoV-2 variants, and this property correlates with improved clinical COVID-19 outcome, a causal relationship between Fc effector functions and vaccine-mediated protection against infection has not been established. Here, using passive and active immunization approaches in wild-type and Fc-gamma receptor (FcgR) KO mice, we determined the requirement for Fc effector functions to protect against SARS-CoV-2 infection. The antiviral activity of passively transferred immune serum was lost against multiple SARS-CoV-2 strains in mice lacking expression of activating FcgRs, especially murine FcgR III (CD16), or depleted of alveolar macrophages. After immunization with the preclinical mRNA-1273 vaccine, protection against Omicron BA.5 infection in the respiratory tract also was lost in mice lacking FcgR III. Our passive and active immunization studies in mice suggest that Fc-FcgR engagement and alveolar macrophages are required for vaccine-induced antibody-mediated protection against infection by antigenically changed SARS-CoV-2 variants, including Omicron strains.Competing Interest StatementM.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences, Moderna, and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Emergent BioSolutions, and Moderna. R.S.B is a member of the Scientific Advisory Board of VaxArt and Adagio, has consulted for Takeda, and received unrelated funding from J&J and Pfizer. G.A. is a founder/equity holder in Seroymx Systems and Leyden Labs and has served as a scientific advisor for Sanofi Vaccines. G.A. has collaborative agreements with GlaxoSmithKline, Merck, Abbvie, Sanofi, Medicago, BioNtech, Moderna, BMS, Novavax, SK Biosciences, Gilead, and Sanaria. D.K.E. and G.A. are employees and shareholder in Moderna, Inc. All other authors declare no conflicts of interest.
Emerging SARS-CoV-2 variants with antigenic changes in the spike protein are neutralized less efficiently by serum antibodies elicited by legacy vaccines against the ancestral Wuhan-1 virus. Nonetheless, these vaccines, including mRNA-1273 and BNT162b2, retained their ability to protect against severe disease and death, suggesting that other aspects of immunity control infection in the lung. Although vaccine-elicited antibodies can bind Fc gamma receptors (FcγRs) and mediate effector functions against SARS-CoV-2 variants, and this property correlates with improved clinical COVID-19 outcome, a causal relationship between Fc effector functions and vaccine-mediated protection against infection has not been established. Here, using passive and active immunization approaches in wild-type and Fc-gamma receptor (FcγR) KO mice, we determined the requirement for Fc effector functions to protect against SARS-CoV-2 infection. The antiviral activity of passively transferred immune serum was lost against multiple SARS-CoV-2 strains in mice lacking expression of activating FcγRs, especially murine FcγR III (CD16), or depleted of alveolar macrophages. After immunization with the preclinical mRNA-1273 vaccine, protection against Omicron BA.5 infection in the respiratory tract also was lost in mice lacking FcγR III. Our passive and active immunization studies in mice suggest that Fc-FcγR engagement and alveolar macrophages are required for vaccine-induced antibody-mediated protection against infection by antigenically changed SARS-CoV-2 variants, including Omicron strains.Emerging SARS-CoV-2 variants with antigenic changes in the spike protein are neutralized less efficiently by serum antibodies elicited by legacy vaccines against the ancestral Wuhan-1 virus. Nonetheless, these vaccines, including mRNA-1273 and BNT162b2, retained their ability to protect against severe disease and death, suggesting that other aspects of immunity control infection in the lung. Although vaccine-elicited antibodies can bind Fc gamma receptors (FcγRs) and mediate effector functions against SARS-CoV-2 variants, and this property correlates with improved clinical COVID-19 outcome, a causal relationship between Fc effector functions and vaccine-mediated protection against infection has not been established. Here, using passive and active immunization approaches in wild-type and Fc-gamma receptor (FcγR) KO mice, we determined the requirement for Fc effector functions to protect against SARS-CoV-2 infection. The antiviral activity of passively transferred immune serum was lost against multiple SARS-CoV-2 strains in mice lacking expression of activating FcγRs, especially murine FcγR III (CD16), or depleted of alveolar macrophages. After immunization with the preclinical mRNA-1273 vaccine, protection against Omicron BA.5 infection in the respiratory tract also was lost in mice lacking FcγR III. Our passive and active immunization studies in mice suggest that Fc-FcγR engagement and alveolar macrophages are required for vaccine-induced antibody-mediated protection against infection by antigenically changed SARS-CoV-2 variants, including Omicron strains.
Emerging SARS-CoV-2 variants with antigenic changes in the spike protein are neutralized less efficiently by serum antibodies elicited by legacy vaccines against the ancestral Wuhan-1 virus. Nonetheless, these vaccines, including mRNA-1273 and BNT162b2, retained their ability to protect against severe disease and death, suggesting that other aspects of immunity control infection in the lung. Although vaccine-elicited antibodies can bind Fc gamma receptors (FcγRs) and mediate effector functions against SARS-CoV-2 variants, and this property correlates with improved clinical COVID-19 outcome, a causal relationship between Fc effector functions and vaccine-mediated protection against infection has not been established. Here, using passive and active immunization approaches in wild-type and Fc-gamma receptor (FcγR) KO mice, we determined the requirement for Fc effector functions to protect against SARS-CoV-2 infection. The antiviral activity of passively transferred immune serum was lost against multiple SARS-CoV-2 strains in mice lacking expression of activating FcγRs, especially murine FcγR III (CD16), or depleted of alveolar macrophages. After immunization with the preclinical mRNA-1273 vaccine, protection against Omicron BA.5 infection in the respiratory tract also was lost in mice lacking FcγR III. Our passive and active immunization studies in mice suggest that Fc-FcγR engagement and alveolar macrophages are required for vaccine-induced antibody-mediated protection against infection by antigenically changed SARS-CoV-2 variants, including Omicron strains.
Author Whitener, Bradley M
Baric, Ralph S
Alter, Galit
Liu, Meizi
Chicz, Taras M
Mackin, Samantha R
Edwards, Darin K
McNamara, Ryan P
Diamond, Michael S
Karl, Courtney E
Desai, Pritesh
Author_xml – sequence: 1
  givenname: Samantha R
  surname: Mackin
  fullname: Mackin, Samantha R
  organization: Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO
– sequence: 2
  givenname: Pritesh
  surname: Desai
  fullname: Desai, Pritesh
  organization: Department of Medicine, Washington University School of Medicine, St. Louis, MO
– sequence: 3
  givenname: Bradley M
  surname: Whitener
  fullname: Whitener, Bradley M
  organization: Department of Medicine, Washington University School of Medicine, St. Louis, MO
– sequence: 4
  givenname: Courtney E
  surname: Karl
  fullname: Karl, Courtney E
  organization: Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO
– sequence: 5
  givenname: Meizi
  surname: Liu
  fullname: Liu, Meizi
  organization: Department of Medicine, Washington University School of Medicine, St. Louis, MO
– sequence: 6
  givenname: Ralph S
  surname: Baric
  fullname: Baric, Ralph S
  organization: Department of Epidemiology, University of North Carolina, Chapel Hill, NC
– sequence: 7
  givenname: Darin K
  surname: Edwards
  fullname: Edwards, Darin K
  organization: Moderna, Inc., Cambridge MA
– sequence: 8
  givenname: Taras M
  surname: Chicz
  fullname: Chicz, Taras M
  organization: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA
– sequence: 9
  givenname: Ryan P
  surname: McNamara
  fullname: McNamara, Ryan P
  organization: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA
– sequence: 10
  givenname: Galit
  surname: Alter
  fullname: Alter, Galit
  organization: Andrew M. and Jane M. Bursky the Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO
– sequence: 11
  givenname: Michael S
  surname: Diamond
  fullname: Diamond, Michael S
  organization: Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St. Louis, MO
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36482975$$D View this record in MEDLINE/PubMed
BookMark eNpdkUtOHDEQhq2ICAjhANlElrLJpgeX3e52L9EohEhIkSDJtuVHGRnN2IPdjZhD5DS5R86EgUmIsqrXV3-pqt6QvZgiEvIO2AKAwQlnnFdvwfuFBAXQvyKHvBt4oziTe__4B-S4lBvGGB86EH27Tw5E1yo-9PKQ_Dyzv3_RjBY3U8qNww1Gh3GiOk7BJLel6D3aWqN-jnYKKRaqM9aW2zlkdNTX0p22NkSkm5wmfIKovtYhlomG6HcZs30SvcYYbO3IoUaFJk-vTi-vmmX60fC35LXXq4LHO3tEvp99-rY8by6-fv6yPL1oDAfZN06hUI4L5TvhgStsuXFaMuW9gQEtuM7pVqJWcjBtr5BrK40X1qqeCQviiHx81jUh5ftwN25yWOu8HR-POgKMvB-fj_qC1t1uZyzTuA7F4mqlI6a5VFIKAUx0XUU__IfepDnHukilWgDeDu2j4PsdNZs1ur-j__xEPABKKJFo
ContentType Journal Article
Paper
Copyright 2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (“the License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022, Posted by Cold Spring Harbor Laboratory
Copyright_xml – notice: 2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (“the License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022, Posted by Cold Spring Harbor Laboratory
DBID NPM
8FE
8FH
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
GNUQQ
HCIFZ
LK8
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
FX.
DOI 10.1101/2022.11.27.518117
DatabaseName PubMed
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection (ProQuest)
ProQuest Central
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central
ProQuest Central Student
ProQuest SciTech Premium Collection
Biological Sciences
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
bioRxiv
DatabaseTitle PubMed
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Biological Science Collection
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
Biological Science Database
ProQuest SciTech Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Academic UKI Edition
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
MEDLINE - Academic

PubMed
Database_xml – sequence: 1
  dbid: FX.
  name: bioRxiv
  url: https://www.biorxiv.org/
  sourceTypes: Open Access Repository
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2692-8205
Edition 1.1
ExternalDocumentID 2022.11.27.518117v1
36482975
Genre Preprint
Working Paper/Pre-Print
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: R01 AI157155
– fundername: NIAID NIH HHS
  grantid: R01 AI110700
– fundername: NIAID NIH HHS
  grantid: 75N93019C00051
– fundername: NIAID NIH HHS
  grantid: 75N93021C00014
GroupedDBID 8FE
8FH
AFKRA
ALMA_UNASSIGNED_HOLDINGS
BBNVY
BENPR
BHPHI
HCIFZ
LK8
M7P
NPM
NQS
PHGZT
PIMPY
PROAC
RHI
ABUWG
AZQEC
CCPQU
COVID
DWQXO
GNUQQ
PHGZM
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
FX.
ID FETCH-LOGICAL-b2157-d8e38d238f63f128e42bda508ffb19ec1d6da45ea859b478e2ac5bf3cc8703c13
IEDL.DBID FX.
ISSN 2692-8205
IngestDate Tue Jan 07 18:53:04 EST 2025
Mon Jul 21 09:19:06 EDT 2025
Fri Jul 25 09:16:44 EDT 2025
Thu Apr 03 07:08:45 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
License This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b2157-d8e38d238f63f128e42bda508ffb19ec1d6da45ea859b478e2ac5bf3cc8703c13
Notes SourceType-Working Papers-1
ObjectType-Working Paper/Pre-Print-1
content type line 50
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
Competing Interest Statement: M.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences, Moderna, and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Emergent BioSolutions, and Moderna. R.S.B is a member of the Scientific Advisory Board of VaxArt and Adagio, has consulted for Takeda, and received unrelated funding from J&J and Pfizer. G.A. is a founder/equity holder in Seroymx Systems and Leyden Labs and has served as a scientific advisor for Sanofi Vaccines. G.A. has collaborative agreements with GlaxoSmithKline, Merck, Abbvie, Sanofi, Medicago, BioNtech, Moderna, BMS, Novavax, SK Biosciences, Gilead, and Sanaria. D.K.E. and G.A. are employees and shareholder in Moderna, Inc. All other authors declare no conflicts of interest.
ORCID 0000-0002-8791-3165
OpenAccessLink https://www.biorxiv.org/content/10.1101/2022.11.27.518117
PMID 36482975
PQID 2741124947
PQPubID 2050091
PageCount 42
ParticipantIDs biorxiv_primary_2022_11_27_518117
proquest_miscellaneous_2753310366
proquest_journals_2741124947
pubmed_primary_36482975
PublicationCentury 2000
PublicationDate 20221128
PublicationDateYYYYMMDD 2022-11-28
PublicationDate_xml – month: 11
  year: 2022
  text: 20221128
  day: 28
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Cold Spring Harbor
PublicationTitle bioRxiv
PublicationTitleAlternate bioRxiv
PublicationYear 2022
Publisher Cold Spring Harbor Laboratory Press
Cold Spring Harbor Laboratory
Publisher_xml – name: Cold Spring Harbor Laboratory Press
– name: Cold Spring Harbor Laboratory
References 37012355 - Nat Microbiol. 2023 Apr;8(4):569-580. doi: 10.1038/s41564-023-01359-1
Scheaffer (2022.11.27.518117v1.33) 2022
Goldblatt, Alter, Crotty, Plotkin (2022.11.27.518117v1.57) 2022; 310
Wang (2022.11.27.518117v1.38) 2022; 219
Heyman (2022.11.27.518117v1.46) 2014; 382
Gu (2022.11.27.518117v1.28) 2020; 369
Tarke (2022.11.27.518117v1.17) 2022; 185
Elliott (2022.11.27.518117v1.11) 2022; 375
Cameroni (2022.11.27.518117v1.14) 2022; 602
Brasu (2022.11.27.518117v1.18) 2022; 23
Kaplonek (2022.11.27.518117v1.39) 2022; 14
Brown (2022.11.27.518117v1.76) 2012; 386
Stadlbauer (2022.11.27.518117v1.72) 2020; 57
Botto (2022.11.27.518117v1.65) 1998; 19
Bournazos, DiLillo, Ravetch (2022.11.27.518117v1.52) 2014; 382
Laidlaw (2022.11.27.518117v1.35) 2013; 9
Nelson (2022.11.27.518117v1.66) 2020; 6
Beaudoin-Bussières (2022.11.27.518117v1.43) 2022; 38
Nimmerjahn (2022.11.27.518117v1.53) 2010; 107
Cobb (2022.11.27.518117v1.26) 2022; 3
Ioan-Facsinay (2022.11.27.518117v1.64) 2002; 16
Ackerman, Barouch, Alter (2022.11.27.518117v1.24) 2017; 275
Ravetch, Bolland (2022.11.27.518117v1.51) 2001; 19
Case (2022.11.27.518117v1.20) 2022; 13
Yamin (2022.11.27.518117v1.44) 2021; 599
Davis-Gardner (2022.11.27.518117v1.49) 2022
Chen (2022.11.27.518117v1.62) 2021
Pincetic (2022.11.27.518117v1.50) 2014; 15
Halfmann (2022.11.27.518117v1.54) 2022
Winkler (2022.11.27.518117v1.27) 2021; Jvi0151121
Richardson, Moore (2022.11.27.518117v1.23) 2021; 25
Chong (2022.11.27.518117v1.34) 2022; 39
Zhu (2022.11.27.518117v1.16) 2022; 20
Bournazos, Gupta, Ravetch (2022.11.27.518117v1.58) 2020; 20
Hassett (2022.11.27.518117v1.68) 2019; 15
Ying (2022.11.27.518117v1.30) 2021; eabm3302
Wang (2022.11.27.518117v1.12) 2022; 608
Dinnon (2022.11.27.518117v1.25) 2020; 586
Bates (2022.11.27.518117v1.3) 2021; 12
VanBlargan (2022.11.27.518117v1.73) 2021
Hederman (2022.11.27.518117v1.7) 2022
Chalkias (2022.11.27.518117v1.8) 2022; 387
Richardson (2022.11.27.518117v1.22) 2022; 30
Winkler (2022.11.27.518117v1.41) 2021; 184
Zohar (2022.11.27.518117v1.19) 2020; 183
Corbett (2022.11.27.518117v1.67) 2020; 586
Misharin, Morales-Nebreda, Mutlu, Budinger, Perlman (2022.11.27.518117v1.59) 2013; 49
Krause (2022.11.27.518117v1.1) 2021; 385
Li (2022.11.27.518117v1.32) 2022; 23
Brown (2022.11.27.518117v1.75) 2017; 443
Grunst, Uchil (2022.11.27.518117v1.15) 2022; 3
Zhuang (2022.11.27.518117v1.31) 2021; 218
Cao (2022.11.27.518117v1.13) 2021
Hassan (2022.11.27.518117v1.70) 2021
Khoury (2022.11.27.518117v1.4) 2021; 27
Case, Bailey, Kim, Chen, Diamond (2022.11.27.518117v1.74) 2020; 548
Zang (2022.11.27.518117v1.61) 2020; 5
Kaplonek (2022.11.27.518117v1.6) 2022; 55
Amanat, Krammer (2022.11.27.518117v1.2) 2020; 52
Amanat (2022.11.27.518117v1.71) 2021; 184
Ying (2022.11.27.518117v1.29) 2022; 185
Chemaitelly (2022.11.27.518117v1.37) 2021; 27
Fransen (2022.11.27.518117v1.48) 2018; 200
Sefik (2022.11.27.518117v1.56) 2022; 606
Cromer (2022.11.27.518117v1.5) 2022; 75
Bates (2022.11.27.518117v1.21) 2022; 41
Schäfer (2022.11.27.518117v1.42) 2021; 218
Bowman (2022.11.27.518117v1.40) 2022; 13
Junqueira (2022.11.27.518117v1.55) 2022; 606
Roy (2022.11.27.518117v1.69) 2011; 13
Mades (2022.11.27.518117v1.45) 2021; 11
Chen (2022.11.27.518117v1.63) 2021
Andrews (2022.11.27.518117v1.10) 2022
Accorsi (2022.11.27.518117v1.36) 2022; 327
Schyns, Bureau, Marichal (2022.11.27.518117v1.60) 2018; 2018
Cele (2022.11.27.518117v1.9) 2022; 602
Hamano, Arase, Saisho, Saito (2022.11.27.518117v1.47) 2000; 164
References_xml – reference: 37012355 - Nat Microbiol. 2023 Apr;8(4):569-580. doi: 10.1038/s41564-023-01359-1
– volume: 6
  start-page: eaaz6893
  year: 2020
  ident: 2022.11.27.518117v1.66
  article-title: Impact of mRNA chemistry and manufacturing process on innate immune activation
  publication-title: Science advances
– volume: 12
  start-page: 5135
  year: 2021
  ident: 2022.11.27.518117v1.3
  article-title: Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
  publication-title: Nat Commun
– volume: 608
  start-page: 603
  year: 2022
  end-page: 608
  ident: 2022.11.27.518117v1.12
  article-title: Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
  publication-title: Nature
– volume: 375
  start-page: 1406
  year: 2022
  end-page: 1411
  ident: 2022.11.27.518117v1.11
  article-title: Rapid increase in Omicron infections in England during December 2021: REACT-1 study
  publication-title: Science
– volume: 275
  start-page: 262
  year: 2017
  end-page: 270
  ident: 2022.11.27.518117v1.24
  article-title: Systems serology for evaluation of HIV vaccine trials
  publication-title: Immunol Rev
– volume: 219
  year: 2022
  ident: 2022.11.27.518117v1.38
  article-title: Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans
  publication-title: J Exp Med
– volume: 382
  start-page: 237
  year: 2014
  end-page: 248
  ident: 2022.11.27.518117v1.52
  article-title: humanized mice to study FcγR function
  publication-title: Curr Top Microbiol Immunol
– volume: 369
  start-page: 1603
  year: 2020
  end-page: 1607
  ident: 2022.11.27.518117v1.28
  article-title: Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
  publication-title: Science
– volume: 23
  start-page: 543
  year: 2022
  end-page: 555
  ident: 2022.11.27.518117v1.32
  article-title: Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
  publication-title: Nat Immunol
– volume: 27
  start-page: 1614
  year: 2021
  end-page: 1621
  ident: 2022.11.27.518117v1.37
  article-title: mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
  publication-title: Nat Med
– volume: 386
  start-page: 117
  year: 2012
  end-page: 123
  ident: 2022.11.27.518117v1.76
  article-title: High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples
  publication-title: J Immunol Methods
– volume: 9
  start-page: e1003207
  year: 2013
  ident: 2022.11.27.518117v1.35
  article-title: Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity
  publication-title: PLoS Pathog
– year: 2021
  ident: 2022.11.27.518117v1.13
  article-title: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
  publication-title: Nature
– year: 2021
  ident: 2022.11.27.518117v1.73
  article-title: A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
  publication-title: Immunity
– volume: 55
  start-page: 355
  year: 2022
  end-page: 365
  ident: 2022.11.27.518117v1.6
  article-title: mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern
  publication-title: Immunity
– year: 2022
  ident: 2022.11.27.518117v1.10
  article-title: Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
  publication-title: N Engl J Med
– volume: 185
  start-page: 1572
  year: 2022
  end-page: 1587
  ident: 2022.11.27.518117v1.29
  article-title: Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice
  publication-title: Cell
– volume: 183
  start-page: 1508
  year: 2020
  end-page: 1519
  ident: 2022.11.27.518117v1.19
  article-title: Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality
  publication-title: Cell
– volume: 327
  start-page: 639
  year: 2022
  end-page: 651
  ident: 2022.11.27.518117v1.36
  article-title: Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants
  publication-title: Jama
– volume: 599
  start-page: 465
  year: 2021
  end-page: 470
  ident: 2022.11.27.518117v1.44
  article-title: Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
  publication-title: Nature
– volume: 75
  start-page: e878
  year: 2022
  end-page: e879
  ident: 2022.11.27.518117v1.5
  article-title: Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial
  publication-title: Clin Infect Dis
– volume: 11
  start-page: 24448
  year: 2021
  ident: 2022.11.27.518117v1.45
  article-title: Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination
  publication-title: Sci Rep
– volume: 20
  start-page: 633
  year: 2020
  end-page: 643
  ident: 2022.11.27.518117v1.58
  article-title: The role of IgG Fc receptors in antibody-dependent enhancement
  publication-title: Nat Rev Immunol
– volume: 184
  start-page: 3936
  year: 2021
  end-page: 3948
  ident: 2022.11.27.518117v1.71
  article-title: SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
  publication-title: Cell
– year: 2022
  ident: 2022.11.27.518117v1.7
  article-title: SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations
  publication-title: medRxiv: the preprint server for health sciences
– volume: 3
  start-page: 188
  year: 2022
  end-page: 203
  ident: 2022.11.27.518117v1.26
  article-title: A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques
  publication-title: Med (New York, N.Y.)
– volume: Jvi0151121
  year: 2021
  ident: 2022.11.27.518117v1.27
  article-title: SARS-CoV-2 causes lung infection without severe disease in human ACE2 knock-in mice
  publication-title: J Virol
– volume: 52
  start-page: 583
  year: 2020
  end-page: 589
  ident: 2022.11.27.518117v1.2
  article-title: SARS-CoV-2 Vaccines: Status Report
  publication-title: Immunity
– volume: 164
  start-page: 6113
  year: 2000
  end-page: 6119
  ident: 2022.11.27.518117v1.47
  article-title: Immune complex and Fc receptor-mediated augmentation of antigen presentation for in vivo Th cell responses
  publication-title: J Immunol
– volume: 49
  start-page: 503
  year: 2013
  end-page: 510
  ident: 2022.11.27.518117v1.59
  article-title: Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung
  publication-title: American journal of respiratory cell and molecular biology
– year: 2022
  ident: 2022.11.27.518117v1.33
  article-title: Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice
  publication-title: Nat Med
– year: 2022
  ident: 2022.11.27.518117v1.49
  article-title: mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1
  publication-title: bioRxiv
– volume: 57
  start-page: e100
  year: 2020
  ident: 2022.11.27.518117v1.72
  article-title: SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup
  publication-title: Curr Protoc Microbiol
– volume: 16
  start-page: 391
  year: 2002
  end-page: 402
  ident: 2022.11.27.518117v1.64
  article-title: FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection
  publication-title: Immunity
– volume: eabm3302
  year: 2021
  ident: 2022.11.27.518117v1.30
  article-title: Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
  publication-title: Sci Transl Med
– volume: 13
  start-page: e0164722
  year: 2022
  ident: 2022.11.27.518117v1.40
  article-title: Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity
  publication-title: mBio
– volume: 387
  start-page: 1279
  year: 2022
  end-page: 1291
  ident: 2022.11.27.518117v1.8
  article-title: A Bivalent Omicron-Containing Booster Vaccine against Covid-19
  publication-title: N Engl J Med
– volume: 39
  start-page: 110799
  year: 2022
  ident: 2022.11.27.518117v1.34
  article-title: Nasally delivered interferon-λ protects mice against infection by SARS-CoV-2 variants including Omicron
  publication-title: Cell Rep
– volume: 200
  start-page: 2615
  year: 2018
  end-page: 2626
  ident: 2022.11.27.518117v1.48
  article-title: A Restricted Role for FcγR in the Regulation of Adaptive Immunity
  publication-title: J Immunol
– volume: 27
  start-page: 1205
  year: 2021
  end-page: 1211
  ident: 2022.11.27.518117v1.4
  article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
  publication-title: Nat Med
– volume: 19
  start-page: 56
  year: 1998
  end-page: 59
  ident: 2022.11.27.518117v1.65
  article-title: Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
  publication-title: Nat Genet
– volume: 19
  start-page: 275
  year: 2001
  end-page: 290
  ident: 2022.11.27.518117v1.51
  article-title: IgG Fc receptors
  publication-title: Annu Rev Immunol
– volume: 14
  start-page: eabm2311
  year: 2022
  ident: 2022.11.27.518117v1.39
  article-title: mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions
  publication-title: Sci Transl Med
– volume: 13
  start-page: 17
  year: 2011
  end-page: 25
  ident: 2022.11.27.518117v1.69
  article-title: Creation of a panel of vectors based on ape adenovirus isolates
  publication-title: J Gene Med
– year: 2022
  ident: 2022.11.27.518117v1.54
  article-title: SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
  publication-title: Nature
– volume: 443
  start-page: 33
  year: 2017
  end-page: 44
  ident: 2022.11.27.518117v1.75
  article-title: Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles
  publication-title: J Immunol Methods
– volume: 185
  start-page: 847
  year: 2022
  end-page: 859
  ident: 2022.11.27.518117v1.17
  article-title: SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron
  publication-title: Cell
– volume: 218
  year: 2021
  ident: 2022.11.27.518117v1.42
  article-title: Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo
  publication-title: J Exp Med
– volume: 13
  start-page: 3824
  year: 2022
  ident: 2022.11.27.518117v1.20
  article-title: Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains
  publication-title: Nat Commun
– volume: 184
  start-page: 1804
  year: 2021
  end-page: 1820
  ident: 2022.11.27.518117v1.41
  article-title: Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
  publication-title: Cell
– volume: 602
  start-page: 664
  year: 2022
  end-page: 667
  ident: 2022.11.27.518117v1.14
  article-title: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
  publication-title: Nature
– volume: 586
  start-page: 560
  year: 2020
  end-page: 566
  ident: 2022.11.27.518117v1.25
  article-title: A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures
  publication-title: Nature
– volume: 15
  start-page: 707
  year: 2014
  end-page: 716
  ident: 2022.11.27.518117v1.50
  article-title: Type I and type II Fc receptors regulate innate and adaptive immunity
  publication-title: Nat Immunol
– year: 2021
  ident: 2022.11.27.518117v1.63
  article-title: In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
  publication-title: Nature
– volume: 3
  start-page: 100540
  year: 2022
  ident: 2022.11.27.518117v1.15
  article-title: Fc effector cross-reactivity: A hidden arsenal against SARS-CoV-2’s evasive maneuvering
  publication-title: Cell reports. Medicine
– volume: 25
  start-page: 467
  year: 2021
  end-page: 477
  ident: 2022.11.27.518117v1.23
  article-title: Targeting Fc effector function in vaccine design
  publication-title: Expert Opin Ther Targets
– volume: 606
  start-page: 576
  year: 2022
  end-page: 584
  ident: 2022.11.27.518117v1.55
  article-title: FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation
  publication-title: Nature
– volume: 2018
  start-page: 5160794
  year: 2018
  ident: 2022.11.27.518117v1.60
  article-title: Lung Interstitial Macrophages: Past, Present, and Future
  publication-title: J Immunol Res
– volume: 602
  start-page: 654
  year: 2022
  end-page: 656
  ident: 2022.11.27.518117v1.9
  article-title: Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
  publication-title: Nature
– volume: 38
  start-page: 110368
  year: 2022
  ident: 2022.11.27.518117v1.43
  article-title: A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection
  publication-title: Cell Rep
– volume: 218
  year: 2021
  ident: 2022.11.27.518117v1.31
  article-title: Mapping and role of T cell response in SARS-CoV-2-infected mice
  publication-title: J Exp Med
– volume: 41
  start-page: 111544
  year: 2022
  ident: 2022.11.27.518117v1.21
  article-title: BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age
  publication-title: Cell Rep
– year: 2021
  ident: 2022.11.27.518117v1.62
  article-title: Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
  publication-title: Nat Med
– year: 2021
  ident: 2022.11.27.518117v1.70
  article-title: A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques
  publication-title: Cell Reports Medicine
– volume: 548
  start-page: 39
  year: 2020
  end-page: 48
  ident: 2022.11.27.518117v1.74
  article-title: Growth, detection, quantification, and inactivation of SARS-CoV-2
  publication-title: Virology
– volume: 107
  start-page: 19396
  year: 2010
  end-page: 19401
  ident: 2022.11.27.518117v1.53
  article-title: FcyRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo
  publication-title: Proc Natl Acad Sci U S A
– volume: 586
  start-page: 567
  year: 2020
  end-page: 571
  ident: 2022.11.27.518117v1.67
  article-title: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
  publication-title: Nature
– volume: 30
  start-page: 880
  year: 2022
  end-page: 886
  ident: 2022.11.27.518117v1.22
  article-title: SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
  publication-title: Cell Host Microbe
– volume: 385
  start-page: 179
  year: 2021
  end-page: 186
  ident: 2022.11.27.518117v1.1
  article-title: SARS-CoV-2 Variants and Vaccines
  publication-title: N Engl J Med
– volume: 5
  year: 2020
  ident: 2022.11.27.518117v1.61
  article-title: TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
  publication-title: Sci Immunol
– volume: 20
  start-page: e3001609
  year: 2022
  ident: 2022.11.27.518117v1.16
  article-title: Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates
  publication-title: PLoS Biol
– volume: 606
  start-page: 585
  year: 2022
  end-page: 593
  ident: 2022.11.27.518117v1.56
  article-title: Inflammasome activation in infected macrophages drives COVID-19 pathology
  publication-title: Nature
– volume: 310
  start-page: 6
  year: 2022
  end-page: 26
  ident: 2022.11.27.518117v1.57
  article-title: Correlates of protection against SARS-CoV-2 infection and COVID-19 disease
  publication-title: Immunol Rev
– volume: 23
  start-page: 1445
  year: 2022
  end-page: 1456
  ident: 2022.11.27.518117v1.18
  article-title: Memory CD8(+) T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination
  publication-title: Nat Immunol
– volume: 15
  start-page: 1
  year: 2019
  end-page: 11
  ident: 2022.11.27.518117v1.68
  article-title: Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
  publication-title: Molecular therapy. Nucleic acids
– volume: 382
  start-page: 201
  year: 2014
  end-page: 219
  ident: 2022.11.27.518117v1.46
  article-title: Antibodies as natural adjuvants
  publication-title: Curr Top Microbiol Immunol
SSID ssj0002961374
Score 1.8173113
SecondaryResourceType preprint
Snippet Emerging SARS-CoV-2 variants with antigenic changes in the spike protein are neutralized less efficiently by serum antibodies elicited by legacy vaccines...
SourceID biorxiv
proquest
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
SubjectTerms Alveoli
Antibodies
Antigenic variants
Antiviral activity
Biotechnology
CD16 antigen
COVID-19
Fc receptors
Immune serum
Immunization
Infections
Macrophages
Microbiology
mRNA
Receptor mechanisms
Respiratory tract diseases
Severe acute respiratory syndrome coronavirus 2
Spike protein
Strains (organisms)
Vaccines
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LTtww0KKskHprS2lpaWUkrobGTmLnVLWIFUICISiIW-THGOVAss0uqPsZ_ePOJN7lVG6R_IrG8_S8GDsI1GdD-SikpqebUoGoLGjhAyKPis5VgbKRzy_K05v87K64Sw9u8xRWueKJA6MOnac38iMqs0KNknP9ffZbUNco8q6mFhqv2ARZsEHja_Lz5OLyav3KIisUV0MpZllWSPryW5Fcm4iKZPhL_DqU-rDIKOMSlWDXdP2f5un_CucgeKZv2OTSzqB_yzagfce2xs6Ry232d-rFvX14sBw5FszQcBardrYLjsBqXBeWfAzW6HpO0mtAMG57wCUU_guBo8LKn6wn3zpPBRtwErf3tkGtka8CtVrulsOmiGyNxxWItO1izrvIr39cXYvj7lbI9-xmevLr-FSk7grCoZjXIhhQJqDEjqWKCDzIpQsW9bUYXVaBz0IZbF6ANUXlcm1AWl-4qLxHElc-Uztss-1a-Mi4LZWyGhTgEF63NgVuHCtvXNDGqnKX7Sew1rOxhkZNoEfro5a6HkG_y_ZWAK8TGc3r50vHLdbDSADk1bAtdI80BzXWDAUxHvNhvKj1KarMh9ThTy9v_pm9pv-hFENp9tjmon-EL6hrLNzXhFD_AFUW0zE
  priority: 102
  providerName: ProQuest
Title Fcγ receptor-dependent antibody effector functions are required for vaccine protection against infection by antigenic variants of SARS-CoV-2
URI https://www.ncbi.nlm.nih.gov/pubmed/36482975
https://www.proquest.com/docview/2741124947
https://www.proquest.com/docview/2753310366
https://www.biorxiv.org/content/10.1101/2022.11.27.518117
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bS-wwEA7qIvjm5ejxSoTzmuU0aZv2UcVFBEW8HPat5DI59KVd6iruj_DX-D_8Tc603cUHBd9KkzRlMsk3yczkY-yPJ54N5YKQmo5uUgUiN6CF86g8Klibe8pGvrpOLx7iy3Ey_kT1RWGVtqybl_K59eNTwDauvt3k_hvRXl3i01DqYRJRkuQyG6BKxcTaMBoPF8crMkec0nHvx_yyJVq8fU_fW5ctyozW2eDGTKDZYEtQbbLVjiZytsVeR-79jePSBBPcIYs5b-2Uo1RKW_sZ76Iy6oYTTLWaxE0D2ITifMFztEz5s3HkROf9zQxYiZv_pkTzkM8jsipuZ-1HUatKhy1QO6vpI68Dvzu5vRNn9T8hf7GH0fn92YXoaRSERTzXwmegMo_QHFIVEI4gltYbNMxCsFEOLvKpN3ECJktyG-sMpHGJDco5nMvKRWqbrVR1Bb8ZN6lSRoMCLMJx1VmCHw65y6zXmVHpLjvuRVpMussyChI7bjMKqYtO7LvsYC7sop8vjwVdokM02DEWHy-KUdPJfWEqqJ-oDpqmESIudrPTDdKiF5XGbY7w3g9-YJ-t0TtKKJTZAVuZNk9wiJbF1B6xwen59c3tUatLHxDSzKQ
linkProvider Cold Spring Harbor Laboratory Press
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKrhDcWp6lBYwERxdiJ3FyQAhKV1varqo-UG-pH5MqhyZLdlvYn9E_0t_YmTyWE9x6i2R7HI0_z4zteTD23lOdDeVyITVd3cQKRGpAC-cRPCq3NvUUjXwwicen4Y-z6GyF3faxMORW2cvERlD7ytEd-UdKs0KFkkP9ZfpLUNUoel3tS2i0sNiDxW88ss0-737H9f0g5WjnZHssuqoCwqJ608InoBKPmiqPVY7SGUJpvUE7Jc9tkIILfOxNGIFJotSGOgFpXGRz5RxCW7lAId0HbBgqPMoM2PDbzuTwaHmrI1NUj03qZxmnKGrkp6h7SkXo00WDxK8tqbeigCI80ei2RVX_Ka7_beA2im60yoaHZgr1GluB8gl72FaqXDxlNyMnLszlpeEoIWGKB3XRl8-dc1ycwlZ-wVvnkKrmpC0bQHNTAw4hd2PwHA1kfm0cveXzLkEEduLmwhRopfLeMazkdtEQRXAXDkfgJinnM17l_Pjr0bHYrn4K-Yyd3gvfn7NBWZXwknETK2U0KMAmhJdOIiScpy6xXidGxevsXcfWbNrm7MiI9XjayaTOWtavs82e4Vm3bWfZX5AhiWUzbjh6RTElVFfUBy3kABU_TvOiXajlLCoOm1DlV_8n_pY9Gp8c7Gf7u5O9DfaY_o3CG2WyyQbz-gpeo50zt286cHF2ft94vgOT3hDv
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT9wwELYKqIgbtOXR0tZIvToidhInxwqI6AuhUqq9RX6MUS7JKiyo-yP4Nf0f_CZmkuyKA0jcIo0f0fizZ-x5MfbFU50N5YKQmp5uMgWiMKCF8wgeFawtPEUj_zrLTi-T75N08igWhtwqbd12_-rb3o5PDtt4-g6b-zCmu7rEr0jqKI0pSDKiZ-po6sMKW6NkZ4TschIt31lkgQJLJ6NB88khUPUdp3xezezFTbnJ1s7NFLot9gqaN-z1UC9y_pbdle7-P8czCqZ4VRaLArYzjuypbevnfHDPaDtO8qqHFDcdYBdy-AXPUUXlt8aRNZ2PKRqwETdXpkY9kS9csxpu5_2gCK_aYQ-EaTO75m3gF19_X4ij9q-Q79hlefLn6FSM9RSERcGuhc9B5R5ldMhUQLkEibTeoIYWgo0LcLHPvElSMHla2ETnII1LbVDO4aZWLlbbbLVpG9hl3GRKGQ0KkIQLrPMUBw6Fy63XuVHZHjsYWVpNh6wZFbEd7xuV1NXA9j22v2B2NW6c64qy6VA97ATJB0syQp7sGKaB9obaoI4ao-jFaXaGRVrOorKkDxZ-_4If-MzWz4_L6ue3sx8f2AaRKchQ5vtsddbdwEfUNmb2Uw-nB5KN0PI
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fc%CE%B3+receptor-dependent+antibody+effector+functions+are+required+for+vaccine+protection+against+infection+by+antigenic+variants+of+SARS-CoV-2&rft.jtitle=bioRxiv&rft.au=Mackin%2C+Samantha+R&rft.au=Desai%2C+Pritesh&rft.au=Whitener%2C+Bradley+M&rft.au=Karl%2C+Courtney+E&rft.date=2022-11-28&rft.issn=2692-8205&rft.eissn=2692-8205&rft_id=info:doi/10.1101%2F2022.11.27.518117&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2692-8205&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2692-8205&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2692-8205&client=summon